	_	_	J11
		▐	2
	≢		E
•	≣		b
•		÷	
	Ē	Ξ	Б
	=	=	L

_	Approved for use through 10/31/2002, OMB 0651-0032
Please type a plus sign (+) inside this box ———————————————————————————————————	t and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorr	ney Docket No.	PDC 119	
First Inventor		Solomon S. Steiner	
	DRY POWDER FO	DRMULATIONS OF ANTIHISTAMINE	
Title	FOR NASAL ADMINISTRATION		

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a displicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 19] (preferred arrangement set forth below) Descriptive title of the invention Cross Poferror to Pages 19 ADDRESS TO: Box Patent Application Washington, DC 20231 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on:			
Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification (preferred arrangement set forth below) Descriptive title of the invention 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on:			
Computer Program (Appendix) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages [19]] (preferred arrangement set forth below) Descriptive title of the invention Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) b. Specification Sequence Listing on:			
Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 19] - Descriptive title of the invention 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on:			
Specification [Total Pages 19] a. Computer Readable Form (CRF) - Descriptive title of the invention b. Specification Sequence Listing on:			
- Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table,			
- Reference to sequence listing, a table, i i □ paper or a computer program listing appendix			
- Background of the Invention c Statements verifying identity of above copies			
- Brief Summary of the Invention - Brief Description of the Drawings (if filed) ACCOMPANYING APPLICATION PART			
- Detailed Description 9. Assignment Papers (cover sheet & document			
- Claim(s) - Abstract of the Disclosure 10. 37 CFR 3.73(b) Statement Power of the Disclosure			
(when there is all assignee) — Attorne			
4. Drawing(s) (35 U.S.C. 113) [Total Sheets]			
5. Oath or Declaration [Total Pages 3] 12. Statement (IDS)/PTO-1449 Citations			
a. Unexecuted 13. Preliminary Amendment			
b. Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 17 completed) Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
i. DELETION OF INVENTOR(S) 15 Certified Copy of Priority Document(s)			
named in the prior confication are 27 CFD			
1.63(d)(2) and 1.33(b). Other:			
6. X Application Data Sheet. See 37 CFR 1.76			
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amend			
or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.:/			
Prior application information. Examiner Group / Art Unit			
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied			
Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by ref The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
18. CORRESPONDENCE ADDRESS			
ioi adividai dideliae Undivera			
Customer Number or Bar Code Label Or Correspondence address below			
Customer Number or Bar Code Label Or Correspondence address below Patrea L. Pabst			
Customer Number or Bar Code Label Patrea L. Pabst Name Patrea L. Pabst Arnall Golden & Gregory, LLP			
Customer Number or Bar Code Label Patrea L. Pabst Arnall Golden & Gregory, LLP 2800 One Atlantic Center			
Customer Number or Bar Code Label Patrea L. Pabst Arnall Golden & Gregory, LLP 2800 One Atlantic Center Address 1201 West Peachtree Street			
Customer Number or Bar Code Label Patrea L. Pabst Arnall Golden & Gregory, LLP 2800 One Atlantic Center Address 1201 West Peachtree Street City Atlanta Correspondence address below			
Customer Number or Bar Code Label Patrea L. Pabst Arnall Golden & Gregory, LLP 2800 One Atlantic Center Address 1201 West Peachtree Street			
Customer Number or Bar Code Label Patrea L. Pabst Arnall Golden & Gregory, LLP 2800 One Atlantic Center Address 1201 West Peachtree Street City Atlanta State GA Correspondence address below Correspondence address below			

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to res

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

131333.00	(\$)	355.	.00
-----------	------	------	-----

spond to a collection of milorination diffess it displays a valid ONIS control number.			
Complete if Known			
Application Number			
Filing Date	January 19, 2001		
First Named Inventor	Solomon S. Steiner		
Examiner Name			
Group Art Unit			
Attorney Docket No.	PDC 119		

Date

January 19, 2001

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES			
indicated fees and credit any overpayments to: Deposit	Large Entity Small Entity Fee			
Account 01-2507	Code (\$) Code (\$)	ee Paid		
Number Deposit	105 130 205 65 Surcharge - late filing fee or oath			
Account Name Arnall Golden & Gregory, LLC	127 50 227 25 Surcharge - late provisional filing fee or cover sheet			
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	139 130 139 130 Non-English specification			
Applicant claims small entity status.	147 2,520 147 2,520 For filing a request for ex parte reexamination			
See 37 CFR 1.27 2. X Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
Credit card Money Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
FEE CALCULATION	115 110 215 55 Extension for reply within first month			
	116 390 216 195 Extension for reply within second month			
BASIC FILING FEE Large Entity Small Entity	117 890 217 445 Extension for reply within third month			
Fee Fee Fee Fee Description	118 1,390 218 695 Extension for reply within fourth month			
Code (\$) Code (\$) Fee Paid	128 1,890 228 945 Extension for reply within fifth month			
101 710 201 355 Utility filing fee 355.00	119 310 219 155 Notice of Appeal			
106 320 206 160 Design filing fee	120 310 220 155 Filing a brief in support of an appeal			
107 490 207 245 Plant filing fee 108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing			
	138 1,510 138 1,510 Petition to institute a public use proceeding			
114 150 214 75 Provisional filing fee	140 110 240 55 Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 355.00	141 1,240 241 620 Petition to revive - unintentional			
2. EXTRA CLAIM FEES	142 1,240 242 620 Utility issue fee (or reissue)			
Fee from Extra Claims below Fee Paid	143 440 243 220 Design issue fee			
Total Claims 19 -20 = 0 × 0 = 0	144 600 244 300 Plant issue fee			
Independent 3 -3 = 0 x 0 = 0	122 130 122 130 Petitions to the Commissioner			
Multiple Dependent =	123 50 123 50 Petitions related to provisional applications			
	126 240 126 240 Submission of Information Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20	146 710 246 355 Filing a submission after final rejection			
102 80 202 40 Independent claims in excess of 3	(37 ČFR § 1.129(a))			
104 270 204 135 Multiple dependent claim, if not paid	149 710 249 355 For each additional invention to be examined (37 CFR § 1.129(b))			
109 80 209 40 ** Reissue independent claims over original patent	179 710 279 355 Request for Continued Examination (RCE)			
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	169 900 169 900 Request for expedited examination of a design application			
	Other fee (specify)			
SUBTOTAL (2) (\$) _0_	Reduced by Basic Filing Fee Paid SUBTOTAL (3)			
SUBMITTED BY	Complete (if applicable)			
Name (Print/Type) Patrea L. Rabst	Registration No. 21 294 Telephone 404 972 970	4		
Tunya L. Habot	(Attorney/Agent) 31,204 16/6/10/10/10/10/10/10/10/10/10/10/10/10/10/	<u>'</u>		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Solomon S. Steiner and Bryan R. Wilson

Serial No.: Express Mail Label No.: EL 709 415 605 US

Filed: January 19, 2001 Date of Deposit January 19, 2001

For: DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL

ADMINISTRATION

Assistant Commissioner for Patents Washington, D.C. 20231

EXPRESS MAIL TRANSMITTAL LETTER FOR PATENT APPLICATION AND CERTIFICATE OF MAILING

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, Solomon S. Steiner and Bryan R. Wilson enclose for filing the attached patent application entitled "DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL ADMINISTRATION", which claims priority to U.S.S.N. 60/176,845 filed January 19, 2000. The application includes 1 page of Abstract, 16 pages of specification, 2 pages of claims, and an unexecuted Declaration. An executed Declaration and Assignment to Pharmaceutical Discovery Corporation will be submitted shortly. A check in the amount of \$355.00 to cover the filing fee is enclosed.

This application is entitled to small entity status under 37 C.F.R. § 1.27.

This application is being filed on January 19, 2001 by mailing the application to the Assistant Commissioner for Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10. The Express

"DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL ADMINISTRATION" Filed January 19, 2001
Express Mail Transmittal Letter for
Patent Application and Certificate of Mailing
Express Mail Label No. EL 709 415 605 US

Mail label number appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

The Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment to Deposit Order Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq. ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450

Respectfully submitted,

Patrea L. Pabst Reg. No. 31,284

Date: January 19, 2001

ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 Telefax "DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL ADMINISTRATION" Filed January 19, 2001
Express Mail Transmittal Letter for Patent Application and Certificate of Mailing
Express Mail Label No. EL 709 415 605 US

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this Express Mail Transmittal Letter for Patent Application and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, January 19, 2001, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, mailing label number EL 709 415 605 US, addressed to the Assistant Commissioner for Patents, Washington, D.C. 2023l.

Date: January 19, 2001

(Jean Hicks